Novavax Says FDA Notified Co. It Completed Filing Review Of Final Portion Of Biologics License Application For Its COVID-19 Vaccine And Set PDUFA Review Foal Date In Apr. 2025
Portfolio Pulse from Benzinga Newsdesk
Novavax announced that the FDA has completed the filing review of the final portion of its Biologics License Application for its COVID-19 vaccine. The FDA has set a PDUFA review goal date for April 2025.
June 06, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA has completed the filing review of Novavax's Biologics License Application for its COVID-19 vaccine, with a PDUFA review goal date set for April 2025.
The completion of the FDA's filing review is a significant milestone for Novavax, indicating progress towards potential approval. The set PDUFA date provides a clear timeline for investors, likely boosting short-term sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100